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ABSTRACT
The definition, classification, pathogenesis, test methods, clinical findings, criteria for diagnosis, and therapies
of allergic conjunctival disease are summarized based on the Guidelines for Clinical Management of Allergic
Conjunctival Disease (Second Edition) revised in 2010. Allergic conjunctival disease is defined as “a conjuncti-
val inflammatory disease associated with a Type I allergy accompanied by some subjective or objective symp-
toms.” Allergic conjunctival disease is classified into allergic conjunctivitis, atopic keratoconjunctivitis, vernal
keratoconjunctivitis, and giant papillary conjunctivitis. Representative subjective symptoms include ocular itch-
ing, hyperemia, and lacrimation, whereas objective symptoms include conjunctival hyperemia, swelling, follicu-
losis, and papillae. Patients with vernal keratoconjunctivitis, which is characterized by conjunctival proliferative
changes called giant papilla accompanied by varying extents of corneal lesion, such as corneal erosion and
shield ulcer, complain of foreign body sensation, ocular pain, and photophobia. In the diagnosis of allergic con-
junctival diseases, it is required that type I allergic diathesis is present, along with subjective and objective
symptoms accompanying allergic inflammation. The diagnosis is ensured by proving a type I allergic reaction in
the conjunctiva. Given that the first-line drug for the treatment of allergic conjunctival disease is an antiallergic
eye drop, a steroid eye drop will be selected in accordance with the severity. In the treatment of vernal kerato-
conjunctivitis, an immunosuppressive eye drop will be concomitantly used with the abovementioned drugs.
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1. DEFINITION AND CLASSIFICATION OF
ALLERGIC CONJUNCTIVAL DISEASE
1.1. DEFINITION
Allergic conjunctival disease (ACD) is defined as “a
conjunctival inflammatory disease associated with a
type I allergy accompanied by some subjective and
objective symptoms.” Conjunctivitis associated with
type I allergic reactions is considered allergic con-
junctival disease even if other types of inflammatory
reactions are involved.1
1.2. CLASSIFICATION
ACD is classified into multiple disease types accord-
ing to the presence or absence of proliferative
changes, complicated atopic dermatitis, and mechani-
cal irritation by foreign body (Fig. 1).
1.2.1. Allergic Conjunctivitis (AC) (Fig. 2)
Allergic conjunctival diseases without proliferative
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Fig.　1　Classifi cation of ACD. ACD is classifi ed as follows: (i) AC without proliferative change, (ii) AKC compli-
cated with atopic dermatitis, (iii) VKC with proliferative changes, and (iv) GPC induced by irritation of a foreign 
body. Allergic conjunctivitis are subdivided into SAC and PAC according to the period of onset of the symptoms.
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Fig.　2　Upper palpebral conjunctival fi ndings in AC. 
Mild hyperemia and edema are present.
Fig.　3　Upper palpebral conjunctival fi ndings in AKC. 
Hyperemia, opacity, and sub-conjunctival fi brosis are 
present.
changes in the conjunctiva include seasonal allergic
conjunctivitis (SAC) where symptoms appear in a sea-
sonal manner and perennial allergic conjunctivitis
(PAC) where symptoms persist throughout the year.
1.2.2. Atopic Keratoconjunctivitis (AKC) (Fig. 3)
AKC is a chronic allergic conjunctival disease that
may occur in patients with facial atopic dermatitis. Gi-
ant papillae may be present although many AKC
cases have no proliferative changes.
1.2.3. Vernal Keratoconjunctivitis (VKC) (Fig. 4)
VKC is characterized by conjunctival proliferative
changes such as papillary hyperplasia of the palpebral
conjunctiva or its enlargement, and swelling or limbal
gelatinous hyperplasia. Many VKC cases accompany
atopic dermatitis. Corneal lesions with various severi-
ties including superficial punctate keratitis, corneal
erosion, persistent corneal epithelial defect, corneal
ulcers, or corneal plaque have been observed in VKC.
1.2.4. Giant Papillary Conjunctivitis (GPC) (Fig.
5)
GPC is conjunctivitis that accompanies proliferative
changes in the upper palpebral conjunctiva induced
by mechanical irritations such as contact lenses, ocu-
lar prosthesis, or surgical sutures. Clinically, GPC dif-
fers from VKC by the absence of a corneal lesion and
by having a different papillary form.
2. EPIDEMIOLOGY OF ACD
In surveys of the entire population conducted by the
Allergy Integrated Project Epidemiologic Investiga-
tion Group of the Ministry of Health and Welfare in
1993, the proportion of persons with bilateral ocular
itching was 16.1% in children aged less than 15 and
21.1% in adults. The proportion of persons with aller-
gic conjunctival diseases diagnosed by ophthalmolo-
gists was 12.2% in children and 14.8% in adults. From
these results, the proportion of persons with allergic
Allergic Conjunctival Diseases
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Fig.　4　Upper palpebral conjunctival fi ndings in VKC. 
Conjunctival hyperemia, conjunctival edema, eye dis-
charge, formation of giant papillae are present.
Fig.　5　Upper palpebral conjunctival fi ndings in GPC. 
Hyperemia and dome-like giant papillae are present.
Fig.　6　Age distribution of patients with allergic conjuncti-
val diseases. The number of patients with allergic conjuncti-
val diseases who contacted the facilities was maximum at 
the age of 10 and the number decreased with aging. The 
peak incidence of each disease was also at the age of 10 
and the incidence decreased with aging. (Incidence is cal-
culated by dividing the number of treated patients in each 
age group by the entire population of the same age group in 
Japan. The incidence at the age of 10 is made 1 and the re-
sult is expressed as ratio.) Adapted from reference 1.
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conjunctival diseases in the entire population is esti-
mated to be about 15-20%.
A research group on allergic ocular disease of the
Japan Ophthalmologists Association conducted epide-
miologic surveys of all patients with allergic conjunc-
tival diseases that were treated at 28 facilities (7 uni-
versity attached hospitals, 5 general hospitals, and 16
ophthalmic hospitals and clinics) all over Japan dur-
ing the period from January 1, 1993 to December 31,
1995. They found that female patients with SAC or
PAC outnumbered male patients by 2 : 1, whereas
male patients with VKC outnumbered female patients
by 2 : 1. The number of patients with ACD was maxi-
mum at the age of 10 and the incidence decreased
with aging (Fig. 6). The main subjective symptoms
were an ocular itching, ocular hyperemia, eye dis-
charge, and a foreign body sensation in each disease
type. In SAC, symptoms of allergic rhinitis such as
sneezing, rhinorrhea, nasal blockade were found in
many cases.
3. PATHOPHYSIOLOGY
3.1. NETWORK OF VARIOUS IMMUNE SYSTEM
CELLS AND KERATOCONJUNCTIVAL RESI-
DENT CELLS
The pathological conditions of ACD with lesions in
the conjunctiva is assumed to be caused by interac-
tions between various immune system cells and resi-
dent cells, which are mediated by physiologically ac-
tive substances (e.g. histamine and leukotriene), cy-
tokines, and chemokines.
3.2. EOSINOPHILS AND CYTOTOXIC PROTEINS
Eosinophils are the main effector cells in ACD. Vari-
ous cytotoxic proteins released from eosinophils infil-
trating locally into the conjunctiva are thought to
cause keratoconjunctival disorders such as severe
AKC and VKC (Fig. 7).
3.3. HELPER T AND B CELLS AND CYTOKINES
An immunological feature of AKC and VKC is the in-
filtration of CD4+ helper T cells (Th) and IgE-
producing B cells into the conjunctiva. In normal tu-
nica propia conjunctivae, there are resident CD4+ T
cells and CD8+ T cells.2,3 Since T cell clones infiltrate
into the conjunctiva in VKC patients and produce Th2
cytokines such as IL-4,4 which is detected in high
concentrations in the lacrimal fluid of VKC patients,5
Takamura E et al.
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Fig.　7　Mechanisms of corneal disorder in severe allergic conjunctival diseases. Various 
cytotoxic proteins released from eosinophils and proteases released from mast cells in-
duce corneal epithelial disorders. IL-4 and IL-13 infi ltrate from the defective epithelium into 
the stromal layer to activate the keratocytes and produce chemokines such as TARC, eo-
taxin, and SCF, and cytokines. These molecules attract Th2 cells, eosinophils, and mast 
cells to the cornea. TARC, thymus-and activation-regulated chemokine; CCR4, Chemo-
kine receptor 4; CCR3, Chemokine receptor 3; IL, Interleukin; SCF, stem cell factor; ECP, 
eosinophil cationic protein; MBP, major basic protein; EDN, eosinophil-derived neurotoxin; 
EPO, eosinophil peroxidase.
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it appears that Th2 cells and Th2 cytokines predomi-
nate in VKC. On the other hand, it is reported that in
the conjunctivae of AKC patients, Th1 and Th2 may
be competitive.6 It is also speculated that keratocon-
junctival resident cells may be involved in the etiol-
ogy of ACD by cytokine-stimulated production of
chemokines such as eotaxin7,8 and TARC,9 which
cause eosinophil and Th2 cell migrations from the
circulation respectively (Fig. 7).
4. TEST METHODS
The objective of tests is to prove a type I allergic reac-
tion in the conjunctiva and in the whole body. Clinical
test methods for proving type I allergic reactions in
the conjunctiva include the identification of eosino-
phils in the conjunctiva, instillation provocation test,
and total IgE antibody measurements in lacrimal
fluid. Systemic allergy tests detect antigen specific
IgE antibodies in the skin and serum.
4.1. IDENTIFICATION OF EOSINOPHILS IN THE
CONJUNCTIVA
Eye discharge or ocular secretions collected using
spatulas and tweezers, are smeared onto glass slides,
then stained by Hansel or Giemsa staining methods,
and observed under an optical microscope.10
4.2. INSTILLATION PROVOCATION TEST
When an antigen can be presumed by skin test or se-
rum antigen specific IgE antibody measurements,
this test confirms the presence of conjunctivitis by in-
stillation of a solution of the known antigen. If itching
or hyperemia follows, the case is evaluated as being
positive.
4.3. TOTAL IgE ANTIBODY MEASUREMENT IN
LACRIMAL FLUID
A kit is commercially available to measure the level of
total IgE antibody in lacrimal fluid using an immuno-
chromatography.11
5. THE CLINICAL FEATURE AND EVALU-
ATION CRITERIA
5.1. SUBJECTIVE SYMPTOMS
Representative subjective symptoms for ACD are
itching, foreign body sensation, and eye discharge.
Itching is the most characteristic symptoms in
ACD, but some patients complain of a foreign body
sensation instead. The foreign body sensation is fre-
quently present in ACD. Aside from cases where
slight itching is felt as a foreign body sensation, it is
very likely that when many conjunctival papillae
sweep the cornea at the time of blinking, a foreign
body sensation may occur. In ACD lymphocytes and
eosinophils account for the majority of inflammatory
Allergic Conjunctival Diseases
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Table　1　Clinical evaluation criteria of allergic conjunctival diseases
Palpebral conjunctiva
Hyperemia
Severe Impossible to distinguish individual blood vessels
Moderate Dilatation of many vessels
Mild Dilatation of several vessels
None No manifestations
Swelling
Severe Diffuse marked edema
Moderate Diffuse mild edema
Mild Localized edema
None No manifestations
Follicle
Severe 20 or more follicles
Moderate 10-19 follicles
Mild 1-9 follicles
None No manifestations
Papillae†
Severe Diameter ≥0.6 mm
Moderate Diameter 0.3-0.5 mm
Mild Diameter 0.1-0.2 mm
None No manifestations
Giant papillae
Severe Elevated papillae in 1/2 or more of upper palpebral conjunctiva
Moderate Elevated papillae in less than 1/2 of upper palpebral conjunctiva
Mild Flat giant papillae
None No manifestations
Bulbar conjunctiva
Hyperemia
Severe Vasodilatation of all vessels
Moderate Dilation of many vessels
Mild Dilation of several vessels
None No manifestations
Chemosis
Severe Cyst-like chemosis of entire conjunctiva
Moderate Diffuse thin chemosis
Mild Partial conjunctival swelling
None No manifestations
Limbus
Swelling
Severe In ≥2/3 of circumference
Moderate In 1/3 to 2/3 of circumference
Mild In less than 1/3 of circumference
None No manifestations
Horner-Trantas dots
Severe  ≥9 dots
Moderate 5-8 dots
Mild 1-4 dots
None No manifestations
Cornea Epithelial disorder
Severe Shield ulcer or epithelial erosion
Moderate Superfi cial punctate keratitis with fi lamentary debris
Mild Superfi cial punctate keratitis
None No manifestations
†In cases having giant papillae, papillae and giant papillae should be graded simultaneously.
cells, while neutrophils are few, serous and mucous
discharge is often present, and the nature of the dis-
charge differs from the purulent discharge associated
with bacterial conjunctivitis and viscous and serous
discharges found in viral conjunctivitis.
5.2. OBJECTIVE SYMPTOMS
Conjunctival hyperemia with dilated conjunctival ves-
sels is the most frequent conjunctival finding. Con-
junctival swelling is a finding that is induced by circu-
latory failure of the palpebral conjunctival vessels and
lymphatic vessels. And in many cases, conjunctival
opacity is accompanied. A conjunctival follicle is a
lymphoid follicle seen under the lower palpebral con-
junctival epithelium. This finding can be discrimi-
nated from papillae by the condition of a smooth
Takamura E et al.
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Fig.　8　Palpebral conjunctival hyperemia (moderate). 
Source: reference 12.
Fig.　9　Palpebral conjunctival swelling (moderate). 
Source: reference 12.
Fig.　10　Palpebral conjunctival follicles (severe). 
Source: reference 12.
Fig.　11　Palpebral conjunctival papillae (moderate). 
Source: reference 12.
dome-like prominence, which is surrounded by ves-
sels. Conjunctival papillae is originated from epithe-
lial proliferation in response to inflammation, in
which the epithelium itself is hypertrophic. A vascu-
lar network is present from the center of the promi-
nence, although this network is seen at the upper
palpebral conjunctival fornix physiologically. Papillae
of 1 mm or more in diameter, called giant papillae,
are fibrous proliferative tissues found typically in
VKC and GPC, and a large number of inflammatory
cells such as lymphocytes, mast cells, and eosino-
phils are observed under the epithelium. Conjunctival
edema is caused by leakage of plasma components
from the vessels. Horner-Trantas dots found at the
limbal region are small prominences induced by de-
generation of proliferated conjunctival epithelium, in
which congregated eosinophils may be present. Cor-
neal complications in severe cases include superficial
punctate keratitis, which is a partial defect of the cor-
neal epithelium, exfoliated superficial punctate kerati-
tis, and shield ulcer (shield-shape ulcer), which is a
prolonged corneal epithelial defect.
5.3. CLINICAL EVALUATION CRITERIA OF OB-
JECTIVE SYMPTOMS
Major objective symptoms in each site of the palpe-
bral conjunctiva, bulbar conjunctiva, limbal conjunc-
tiva, and cornea were graded for severity and the
clinical evaluation criteria were made12 Table 1.
5.3.1. Palpebral Conjunctiva
The items evaluated in palpebral conjunctival findings
are hyperemia, swelling, follicles, papillae, and giant
papillae. The criteria in each item are the density of
dilated blood vessels for hyperemia (Fig. 8), the scale
and the presence or absence of opacity for swelling
(Fig. 9), the number of follicles in either side inferior
palpebral conjunctiva where more follicles are ob-
served than in the other side for follicle (Fig. 10). Pa-
pillae are evaluated according to their diameter (Fig.
11). In case with papillae of 1 mm or more in diame-
ter, it is regarded as giant papillae (Fig. 12), which
are evaluated according to the prominence range. In
VKC, the papillar findings are also graded as severe.
5.3.2. Bulbar Conjunctiva
The bulbar conjunctiva is evaluated according to hy-
Allergic Conjunctival Diseases
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Fig.　12　Palpebral conjunctival giant papillae (severe). 
Source: reference 12.
Fig.　13　Palpebral conjunctival hyperemia (severe). 
Source: reference 12.
Fig.　14　Palpebral conjunctival edema (severe).
 Source: reference 12.
Fig.　15　Limbal conjunctiva Horner-Trantas dots (mod-
erate). Source: reference 12.
peremia and chemosis. Since pathologic conditions
are characterized by marked hyperemia (Fig. 13), the
grade of ”severe” hyperemia is defined as entire vas-
cular dilation. Chemosis is evaluated according to its
shape (Fig. 14).
5.3.3. Limbal Conjunctiva
The Horner-Trantas dots is evaluated according to
the number of the dots seen over the entire limbal re-
gion (Fig. 15), and the swelling is evaluated accord-
ing to the range of the salmon pink swelling observed
at the scleral side of the limbus (Fig. 16).
5.3.4. Cornea (Fig. 17, 18)
The severity of the corneal epithelial defect is used as
evaluation criteria. It is assumed in corneal disorders
that superficial punctate keratitis is mildest and exfo-
liated superficial punctate keratitis is the next grade,
and corneal erosion and shield ulcer follow in sever-
ity. Degenerated epithelium and mucin are deposited
on the surface of the cornea and are observed as cor-
neal plaque when corneal epithelium disorder per-
sists. Because the condition may persist even after
the inflammation is alleviated, the presence or ab-
sence of defective epithelium was not included in the
grading evaluation.
6. DIAGNOSIS AND DIFFERENTIAL DIAG-
NOSIS
In the diagnosis of allergic conjunctival diseases, it is
required that type I allergic diathesis is present,
along with subjective and objective symptoms accom-
panying allergic inflammation. The diagnosis is en-
sured by proving a type I allergic reaction in the con-
junctiva (Table 2).
6.1. CLINICAL SYMPTOMS (A)
Frequent subjective symptoms are ocular itching, hy-
peremia, eye discharge, foreign body sensation, ocu-
lar pain, and photophobia. The ocular itching is the
most common among all inflammatory symptoms ac-
companying type I allergic reactions, and is important
as a basis for diagnosis.
Other important symptoms are hyperemia, eye dis-
charge, and lacrimation, although those symptoms
are not specific for allergic conjunctival diseases. For-
eign body sensations, ocular pain, and photophobia
are symptoms accompanying corneal lesions and in-
Takamura E et al.
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Fig.　16　Limbal conjunctival swelling (severe). 
Source: reference 12.
Fig.　17　Corneal epithelium disorder (moderate).
Source: reference 12.
Fig.　18　Corneal epithelium disorder (severe). 
Source: reference 12.
dicate the severity of the inflammation rather than its
diagnostic significance.
Giant papillae, limbal proliferation (limbal gelati-
nous hyperplasia, Horner-Trantas dot), and shield ul-
cer are important objective symptoms and are thus
“highly specific.” Conjunctival edema and follicles,
papillary hyperplasia, and corneal epithelial abrasion
(corneal erosion and exfoliated superficial punctate
keratitis) are “intermediately specific,” and conjuncti-
val hyperemia and superficial punctate keratitis are
“poorly specific.” However, the symptoms and find-
ings that form the basis of diagnoses are slightly dif-
ferent among the diseases as shown in Figure 19.
6.2. PROOF OF TYPE I ALLERGIC DIATHESIS (B)
6.2.1. Systemic Diathesis
Common methods to determine the presence or ab-
sence of allergic diathesis are those detecting serum
antigen specific IgE antibody and skin reaction with a
presumed antigen. In addition, an increase in serum
total IgE antibody, the presence or absence of a famil-
ial history of allergic diseases, and complication of
other allergic disease can be used as references.
6.2.2. Local Diathesis
The proof can be made by increased total IgE anti-
body in lacrimal fluid.
6.3. PROOF OF TYPE I ALLERGIC REACTION (C)
To prove the presence of type I allergic reaction in
the conjunctiva, it is necessary to prove to be positive
for eosinophils in smears of eye discharge or ocular
secretion.
6.4. DIAGNOSIS OF ACD
6.4.1. Seasonal Allergic Conjunctivitis (SAC)
A clinical diagnosis can be made by subjective symp-
toms including ocular itching, lacrimation, hyperemia
and foreign body sensation, and objective symptoms
including conjunctival hyperemia, conjunctival ede-
ma, and conjunctival follicles, which are found annu-
ally during the same season. The most common and
important symptom of SAC is the ocular itching.
Since the majority of SAC cases are conjunctivitis
caused by pollen antigens, complicated symptoms of
rhinitis are observed in 65-70% of cases. A positive
test for serum antigen specific IgE antibody or a posi-
tive skin reaction, even in quasi-definitive diagnoses,
makes it highly probable that a definite clinical diag-
nosis can be made. The serum total IgE antibody may
be normal or mildly increased. The positive agree-
ment rate in the measurement of the total IgE anti-
body in lacrimal fluid is about 70%.11 The exposure to
a large amount of antigens may induce acute bulbar
conjunctival edema.
6.4.2. Perennial Allergic Conjunctivitis (PAC)
A multi-seasonal or almost perennial ocular itching,
lacrimation, hyperemia, and eye discharge are sub-
jective symptoms of PAC and conjunctival hyperemia
and papilla without proliferative change in the con-
junctiva are objective symptoms. Most cases pass
over chronically. The major antigens are house-dust-
mite. Because it is very likely that the clinical symp-
toms are mild and characteristic objective symptoms
Allergic Conjunctival Diseases
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Fig.　19　Diagnostic fl ow-chart of allergic conjunctival diseases.
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Table　2　Diagnostic criteria
Clinical diagnosis (A only) Clinical symptoms specifi c for allergic conjunctival diseases are present.
Quasi-defi nitive diagnosis (A + B) In addition to the clinical diagnosis, positive results for serum antigen specifi c IgE an-tibody or skin reaction with presumed antigens.
Defi nitive diagnosis (A + B + C, A + C) In addition to the clinical diagnosis, or quasi-defi nitive diagnosis, a positive result for eosinophils in the conjunctival smear.
A: Clinical symptoms are present. B: Type I allergic diathesis (systemic and local diathesis) are present. C: Type I allergic reaction in the 
conjunctiva is present.
are lacking, clinical diagnosis can be difficult in some
cases, especially in elderly cases. Since the positive
rate of eosinophils in the conjunctival smear is low,
repetitive testing becomes necessary for the proof in
some cases.
6.4.3. Atopic Keratoconjunctivitis (AKC)
In AKC, the atopic dermatitis is complicated with fa-
cial lesions and conjunctivitis is perennially chronic
with ocular itching, eye discharge, papillary hyperpla-
sia, and corneal lesions. Proliferative lesions such as
giant papillae and limbal lesions are present in some
cases. Long-term chronic inflammation may result in
fornix foreshortening and symblepharon. Increased
total IgE antibodies in serum and lacrimal fluid and
positive results of the serum antigen specific IgE anti-
body are found at high rates.
6.4.4. Vernal Keratoconjunctivitis (VKC)
VKC is a severe allergic conjunctival disease with
proliferative lesions in the conjunctiva. The prolifera-
tive lesion has giant papillae at the upper palpebral
conjunctiva, limbal proliferation (limbal gelatinous
hyperplasia and Horner-Trantas dots), and corneal le-
sions at high rates and easily becomes severe. Char-
acteristic corneal lesions include exfoliated superfi-
cial punctate keratitis, shield ulcer (shield-shape ul-
cer), and corneal plaque. Clinical diagnosis is easy
because the symptoms are characteristic. Major
single-causative antigens are house-dust-mite, and
the reaction with multiple kinds of antigens such as
pollens and animal scurf occurs frequently. Increased
total IgE antibodies in serum and lacrimal fluid and
positive results for serum antigen specific IgE anti-
body are detected at high rates. In addition, a high
positive rate of eosinophils in the conjunctival smear
is found. Consequently, the definitive diagnosis is
easy.
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Table　3　Antiallergic eye drops
Generic names Product names
Mediator antireleasers
Disodium cromoglicate
Intal® ophthalmic solution UD
Intal® ophthalmic solution
Amlexanox Elics® ophthalmic solution
Pemirolast potassium
Alegysal® ophthalmic solution
Pemilaston® ophthalmic solution
Tranilast
Rizaben® ophthalmic solution
Tramelas® ophthalmic solution
Ibudilast
Eyevinal® ophthalmic solution
Ketas® ophthalmic solution
Acitazanolast hydrate Zepelin® ophthalmic solution 0.1%
Histamine H1 receptor antagonists
Ketotifen fumarate
Zaditen® ophthalmic solution UD 0.05%
Zaditen® ophthalmic solution
Levocabastine hydrochloride Livostin® ophthalmic suspension 0.025%
Olopatadine hydrochloride Patanol® ophthalmic solution 0.1%
6.4.5. Giant Papillary Conjunctivitis (GPC)
In cases of contact lenses, ocular prosthesis, or surgi-
cal sutures, clinical diagnosis of GPC is made when
ocular itching, foreign body sensations, and eye dis-
charge are present and conjunctival hyperemia, con-
junctival edema, and papillary hyperplasia are found.
GPC induced by contact lenses is called contact lens
related papillary conjunctivitis. Giant papillary con-
junctivitis represents the most severe cases, which
present with giant papillae of 1 mm or larger in di-
ameter. The involvement of type I allergy is unknown
in some cases and positive results for serum antigen
specific IgE antibody are not frequent. A positive rate
of eosinophils in GPC is rarer than that in other aller-
gic conjunctival diseases.
6.5. DIFFERENTIAL DIAGNOSIS
Infectious conjunctivitis such as viral, bacterial Chla-
mydia, non-inflammatory conjunctival folliculosis, and
dry eye are considered as differential diagnosis.
7. PROPHYLAXIS: SELF-CARE
7.1. AVOIDANCE AND ELIMINATION METHODS
BY TYPES OF ANTIGENS
Perennial avoidance and elimination of antigens can
be achieved by arranging the patient’s daily living en-
vironment, especially their indoor environment. In
contrast, the avoidance of pollen antigens is con-
ducted mainly during the pollen-flying period and it is
necessary to take measures so that the daily activities
of the patient will not be prevented by exposure to
pollens.
7.2. SELF CARE FOR ALLERGIC CONJUNCTIVI-
TIS
7.2.1. Effect of Glasses for Prevention of Pollens
During pollen-flying period, goggle-type glasses are
recommended to carry out daily activities such as rid-
ing a bicycle and having a stroll with a dog, although
even glasses themselves can reduce the amount of
pollen flying into the ocular surface.
7.2.2. Contact Lens Insertion
During the pollen-flying period, it is useful to stop in-
serting contact lenses as much as possible, changing
to glasses to avoid antigens.
7.2.3. Eye Washing by Artificial Tear
Antigens flying into the eye surface can be washed
out by several drops of artificial tear. Because ordi-
nary artificial tear contain preservatives, when instilla-
tion is repeated 4 or more times, an artificial tear
without preservatives is recommended for safety.
Since tap water reduces the stability of the layer of
tears, frequent use of water for washing eyes should
be avoided. Cup-type eye washing tools are not rec-
ommended because skin blurs around the eyes and
antigens attaching to the skin touch the ocular sur-
face.
8. TREATMENT: MEDICAL CARE
8.1. FUNDAMENTALS OF TREATMENT
Drug treatment is the preferred treatment for allergic
conjunctival diseases. The first option is antiallergic
eye drops, which are the basic treatment for allergic
conjunctivitis, followed by the differential use of ster-
oid eye drops as necessary according to the severity.
For severe ACDs (AKC andVKC), additional use of
immunosuppressive eye drops, steroid oral medi-
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Table　4　Steroid eye drops
Generic names
Concentration (%)
0.01 0.02 0.05 0.1 0.25 0.5
Betamethasone sodium phosphate ○ ○
Dexamethasone sodium phosphate ○
Dexamethasone sodium metasulfobenzoate ○ ○ ○
Fluorometholone ○ ○ ○
Hydrocortisone acetate ○
Table　5　Steroid eye ointments
Generic names
Concentration (%)
0.01 0.02 0.05 0.1 0.25
Compounding agent of betamethasone phosphate 
and fradiomycin sulfate ○
Dexamethasone sodium metasulfobenzoate ○
Compounding agent of methylprednisolone and 
fradiomycin sulfate ○
Prednisolone ○
Table　6　Immunosuppressive eye drops
Generic names Product names
Cyclosporin Papilock® mini ophthalmic solution 0.1%
Tacrolimus hydrate Talymus® ophthalmic suspension 0.1%
cines, sub-tarsal conjunctival steroid injection and
surgical treatment such as papillary resection should
be considered.
8.2. ANTIALLERGIC EYE DROPS (Table 3)
Mast cell stabilizer inhibit the degranulation of mast
cells and suppress release of mediators (e.g. hista-
mine, leukotriene, thromboxane A2), consequently,
the early phase reaction to type I allergy is inhibited,
and conjunctival local infiltration of inflammatory
cells is curtailed, resulting in a reduction of the late
phase reaction. Histamine H1 receptor antagonists
block histamine H1 receptors, representative media-
tors released through the degranulation of mast cells,
which results in suppression of hyperemia and ocular
itching.
8.3. STEROIDS
8.3.1. Eye Drops (Table 4)
When a sufficient effect cannot be obtained by antial-
lergic eye drops only, eye drops with a titer corre-
sponding to the severity of inflammation are com-
bined. Local side effects include elevation of intraocu-
lar pressure,13 induction of infection, and cataracts. It
is necessary to measure the intraocular pressure
regularly in children because the incidence of ele-
vated intraocular pressure is high.14
8.3.2. Oral Medicines
Medicines are used for pediatric and other patients
for whom sub-tarsal conjunctival injection is difficult
and for patients with corneal epithelial defect. The
standard administration period is 1-2 weeks in consid-
eration of its side effects. It is necessary to treat pa-
tients with caution for its systemic side effects in co-
operation with internists and pediatricians.
8.3.3. Eye Ointments (Table 5)
When a sufficient effect is not obtained by antiallergic
eye drops only or steroid eye drops cannot be used,
ointments are used. Ointments can be applied before
going to sleep to realize the effect while sleeping. The
same cautions as those in using steroid eye drops are
necessary.
8.3.4. Sub-Tarsal Conjunctival Injection of Ster-
oid Suspension
Triamcinolone acetonide or betamethasone suspen-
sion is injected to the sub-tarsal conjunctiva of the up-
per eyelid in intractable or severe cases. With caution
Takamura E et al.
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Fig.　20　Treatment of ACDs: Proliferative (Vernal keratoconjunctivitis).
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Immunosuppressive eye drops
Antiallergic eye drops
for the elevation of intraocular pressure, it is desir-
able to avoid repeated use or the application to chil-
dren aged less than 10 years.
8.4. IMMUNOSUPPRESSIVE EYE DROPS (Table
6)
At present, 2 kinds of immunosuppressive eye drops
(cyclosporin and tacrolimus) have been approved as
treatment drugs for vernal keratoconjunctivitis. Im-
munosuppressive eye drops are expected to have
equivalent or better effects than steroid eye drops.
Cyclosporin enables the gradual reduction of the
doses of steroid eye drops by combined administra-
tion with antiallergic eye drops and steroid eye
drops.15 Tacrolimus itself also has effects on steroid-
resistant severe cases.16
8.5. SURGICAL TREATMENT
For cases where symptoms are not alleviated by drug
treatment and conjunctival papillary hyperplasia pro-
gresses to cause worsened corneal epithelium disor-
der, a tarsal conjunctival resection, including the pa-
pillae may be performed. While the treatment effect
is immediate, it may recur in some cases. Although
corneal plaques may be removed by surgical curet-
tage, the treatment is performed only when the pa-
thologic condition has been alleviated.
8.6. SELECTION OF TREATMENT METHODS
8.6.1. Allergic Conjunctivitis
The first option is antiallergic eye drops. A mast cell
stabilizer and a histamine H1 receptor antagonist can
be combined. During a period with severe symptoms,
a steroid eye drop is combined. In seasonal allergic
conjunctivitis, when the administration of an antialler-
gic eye drop is started about 2 weeks prior to the pre-
dicted day of the start of flying pollen or at the time
when little symptoms appear, so that the symptoms
decrease during the peak time of flying pollen.17,18
8.6.2. Atopic Keratoconjunctivitis (AKC)
When antiallergic eye drops alone are not sufficiently
effective, a steroid eye drop is combined. At the same
time, it is necessary to treat atopic blepharitis ac-
tively. When a steroid oral medicine is prescribed,
the treatment should be conducted in cooperation
with an internist and a dermatologist.
8.6.3. Vernal Keratoconjunctivitis (VKC)
For moderate or more severe cases such that antial-
lergic eye drops alone are not sufficiently effective, an
immunosuppressive eye drop is added. For severe
cases when improvement cannot be achieved by 2
drugs, a steroid eye drop is added, and depending on
the symptoms, a steroid oral medicine and sub-tarsal
conjunctival steroid injection or surgical treatment
should be attempted. When the symptoms are allevi-
ated, the steroid eye drop should be changed to one
with a lower titer or the number of the instillation
should be gradually decreased, eventually stopping
administration. Then, the treatment is conducted
with an antiallergic eye drop and an immunosuppres-
sive eye drop, and if the remission period becomes
long, control is continued with the antiallergic eye
drop only (Fig. 20).
8.6.4. Giant Papillary Conjunctivitis (GPC)
When a contact lens has a causative, the use of the
contact lens is stopped as a rule, for the purpose of
avoiding mechanical irritation and antigens. The first
option is an antiallergic eye drop and in severe cases,
a steroid eye drop is added. Because there have been
frequent problems in the care of lenses, it is neces-
sary to instruct patients in rub washing and changing
of care tools.
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